Subtherapeutic doses of interleukin-15 augment the anti-tumor effect of interleukin-12 in a B16F10 melanoma model in mice

European Cytokine Network

Volumn 10, Issue 3, 1999, Pages 345-356

  Lasek, Witold ^a   Golłab, Jakub ^a   Maśliński, Włodzimierz ^b   Świtaj, Tomasz ^a   Bałkowiec, Ewa Z ^a   Stokłosa, Tomasz ^a   Giermasz, Adam ^a   Malejczyk, Magdalena ^c   Jakóbisiak, Marck ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF RHEUMATOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Interleukin 12; Interleukin 15; Tumor immunotherapy

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; EXPERIMENTAL NEOPLASM; IMMUNOREGULATION; INTRATUMORAL DRUG ADMINISTRATION; LYMPH NODE; MELANOMA B16; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-15; MACROPHAGES, PERITONEAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NEOPLASM METASTASIS; RECEPTORS, INTERLEUKIN-15; RECEPTORS, INTERLEUKIN-2;

EID: 0032850701     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Wu C, Warrier R R, Wang X, Presky D H, Gately M K. 1997. Regulation of interleukin-12 receptor 2β1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells. Eur. J. Immunol. 27: 147.
2. Skeen M J, Miller M A, Shinnick T M, Ziegler H K. 1996. Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J. Immunol. 156: 1196.
3. Gately M K, Wolitzky A G, Quinn P M, Chizzonite R. 1992. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol. 143: 127.
4. Kobayashi M, Fitz L, Ryan M, Hewick R M, Clark S C, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J. Exp. Med. 170: 827.
5. Shurin M R, Esche C, Peron J M, Lotze M T. 1997. Antitumor activities of IL-12 anti mechanisms of action. In: Adorini L Ed IL-12. Chem. Immunol. vol 68, Basel: Karger, 153.
6. Nastala C L, Edington H D, McKinney T G, Tahara H, Nalesnik M A, Brunda M J, Gately M K, Wolf S F, Schreiber R D, Storkus W J, Lotze M T. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153: 1697.
7. Ogawa M, Yu W G, Umehara K, Iwasaki M, Wijesuriya R, Tsujimura T, Kubo T, Fujiwara H, Hamaoka T. 1998. Multiple roles of interferon-γ in the mediation of interleukin-12 induced tumor regression. Cancer Res. 58: 2426.
8. Brunda M J, Luistro L, Warrier R R, Wright R B, Hubbard B R, Murphy M, Wolf S F, Gately M K. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178: 1223.
9. Brunda M J, Luistro L, Rumennik L, Wright R B, Dvorozniak M, Aglione A, Wigginton J M, Wiltrout R H, Hendrzak J A, Palleroni A V. 1996. Antitumor activity of interleukin-12 in preclinical models. (Review) Cancer Chemother. Pharmacol. 38 (Suppl): S 16.
10. Dias S, Thomas H, Balkwill F. 1998. Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int. J. Cancer 75: 151.
11. Harada M, Tamada K, Abe K, Li T, Onoe Y, Tada H, Takenoyama M, Yasumoto K, Kimura G, Nomoto K. 1998. Systemic administration of interleukin-12 can restore the anti-tumor potential of B16 melanoma-draining lymph node cells impaired at a late tumor-bearing state. Int. J. Cancer 75: 400.
12. Atkins M B, Robertson M J, Gordon M, Lotze M T, Decoste M, Dubois J S, Ritz J, Sandler A B, Edington H D, Garzone P D, Mier J W, Canning C M, Battiato L, Tahara H, Sherman M L. 1997. Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies. Clin. Cancer Res. 3: 409.
13. Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G. 1998. Pilot study of subcutaneous recombinant human interleukin-12 in metastatic melanoma. Clin. Cancer Res. 4: 75.
14. Mu J, Zou J P, Yamamoto N, Tsutsui T, Tai X G, Kobayashi M, Herrmann S, Fujiwara H, Hamaoka T. 1995. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung anti lymph nodes. Cancer Res. 55: 4404.
15. Wigginton J M, Komschlies K L, Back T C, Franco J L, Brunda M J, Wiltrout R II. 1996. Administration of interleukin-12 with pulse interleukin-2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst. 88: 38.
16. Lasek W, Feleszko W, Gołab J. Stokłosa T, Marczak M, Dabrowska A, Malejczyk M, Jakóbisiak M. 1997. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor-α in mice. Cancer Immunol. Immunother. 45: 100.
17. Teicher B A, Ara G, Menon K, Schaub R G. 1996. In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int. J. Cancer 65: 80.
18. Teicher B A, Are G, Buxton D, Leonard J, Schaub R G. 1997. Optimal scheduling of interleukin-12 and chemotherapy in the murine MB-49 bladder carcinoma anti B16 melanoma. Clin. Cancer Res. 3: 1661.
19. Grabstein K H. Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn M A, Ahdieh M, Johnson L, Alderson M R, Watson J D, Anderson D M, Giri J G. 1994. Cloning of a T cell growth factor that interacts with the b chain of the interleukin-2 receptor. Science 264: 965.
20. Carson W E, Fehniger T A, Haldar S, Eckhert K, Lindemann M J, Lai C F, Croce C M, Baumann H, Caligiuri M A. 1997. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. 99: 937.
21. Munger W, Dejoy S Q, Jeyaseelan R Sr, Torley L W, Grabstein K H, Eisenmann J, Paxton R, Cox T, Wick M M, Kerwar S S. 1995. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell. Immunol. 165: 289.
22. + hematopoietic progenitor cells. Blood 87: 2632.
23. Gamero A M, Ussery D, Reintgen D S, Puleo C A, Djeu J Y. 1995. Interleukin-15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res. 55: 4988.
24. Lasek W, Giermasz A, Kuc K, Wańkowiez A, Feleszko W, Golab J, Zagozdzon R, Stoklosa T, Jakóbisiak M. 1996. Potentiation of the anti-tumor effect or actinomycin D by tumor necrosis factor-α in mice: correlation between in vitro and in vivo results. Int. J. Cancer 66: 374.
25. Giri J G, Kumaki S, Ahdieh M, Friend D J, Loomis A, Shanebeck K, Dubose R, Cosman D, Park L S, Anderson D M. 1995. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. EMBO J. 14: 3654.
26. Manfro R, Roy-Chaudhury P, Zeng X X, Steiger J, Nickerson P W, Li Y, Maslinski W, Strom T B. 1997. Interleukin-15 gene transcripts are present in rejecting islet allografts. Transplant. Proc. 29: 1077.
27. Chae D W, Nosaka Y, Strom T B, Maslinski W. 1996. Distribution of IL-15 receptor α-chains on human peripheral blood mononuclear cells and effect of immunosuppressive drugs on receptor expression. J. Immunol. 157: 2813.
28. Kim Y S, Maslinski W, Zheng X X, Stevens A C, Li X C, Tesch G H, Kelley V R, Strom, T B. 1998. Targeting the IL-15 receptor with un antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. J. Immunol. 160: 5742.
29. Gately M K, Worrier R R, Honasoge S, Carvajal D M, Faherty D A, Connaughton S E, Anderson T D, Sarmiento U, Hubbard B R, Murphy M. 1994. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol. 6: 157.
30. Puzanov I J, Bennett M, Kumar V. 1996. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells. J. Immunol. 157: 4282.
31. Carson W E, Giri J G, Lindemann M J, Linett M L, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caliguri M A. 1994. Interleukin-(IL)-15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180: 1395.
32. dim) human NK cells. J. Immunol. 156: 3254.
33. Koblish H K, Hunter C A, Wysocka M, Trinchieri G, Lee W M. 1998. Immune suppression by recombinant interleukin (rIL)-12 involves interferon-γ induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J. Exp. Med. 188: 1603.
34. Brunda M J, Luistro L, Hendrzak J A, Fountoulakis M, Garotta G, Gately M K. 1995. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother Emphasis Tumor Immunol. 17: 71.
35. + T cells for IFN-γ but have differential effects on priming for IL-4. J. Immunol. 156: 2413.
36. Ye W, Young J D, Liu C C. 1996. Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activieties in primary murine lymphocytes. Cell. Immunol. 174: 54.
37. Dinapoli M R, Calderon C L, Lopez D M. 1996. The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduced expression of the inducible nitric oxide synthase gene. J. Exp. Med. 183: 1323.
38. Zou J P, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Hurrmann S H, Wolf S F, Fujiwara H, Hamaoka T. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol. 7: 1135.
39. Tannenbaum C S, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski R M, Hamilton T A. 1996. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156: 693.
40. Allavena P, Giardina G, Bianchi G, Mantovani A. 1997. IL15 is chemotactic for natural killer cells, an stimulates their adhesion to vascular endothelium. J. Leukoc. Biol. 61: 729.
41. McInnes I B, Al-Mughales J, Field M, Leung B P, Huang F P, Dixon R, Sturrock R D, Wilkinson P C, Liew F Y. 1996. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nature Med. 2: 175.
42. Alleva D G, Kaser S B, Monroy M A, Fenton M J, Belier D I. 1997. IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production: evidence for differential receptor subunit utilization associated with stimulation or inhibition. J. Immunol. 159: 2941.
43. Lasek W, Wańkowicz A, Kuc K, Feleszko W, Gołab J, Giermasz A, Wiktor-Jȩdrzejezak W, Jakóbisiak M. 1995. Potentiation of antitumor effects of tumor necrosis factor-α and interferon-γ by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice. Cancer Immunol. Immunother: 40: 315.
44. Leclercq G, Debacker V, de Smedt M, Plum J. 1996. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. J. Exp. Med. 184: 325.
45. a 14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623.
46. + T cells in IL-12-induced immune responses in vivo. J. Immunol. 160: 16.
47. Badolato R, Ponzi A N, Millesimo M, Notarangelo L D, Musso T. 1997. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood 90: 2804.
48. Hunter S E, Waldburger K E, Thibodeaux D K, Schaub R G, Goldman S J, Leonard J P. 1997. Immunoregulation by interleukin-12 in MB49.1 tumor-bearing mice: cellular and cytokinemediated effector mechanisms. Eur. J. Immunol. 27: 3438.
49. Kumaki S, Armitage R, Ahdieh M, Park L, Cosman D. 1996. Interleukin-15 up-regulates interleukin-2 receptor α chain but down-regulates its own high-affinity binding sites on human T and B cells. Eur. J. Immunol. 26: 1235.
50. Wilkinson P C, Liew F Y. 1995. Chemoattraction of human blood T lymphocytes by interleukin-15. J. Exp. Med. 181: 1255.
51. Sgadari C, Angiolillo A L, Tosato G. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87: 3877.
52. Angiolillo A L, Kanegane H, Sgadari C, Reaman G H, Tosato G. 1997. Interleukin-15 promotes angiogenesis in vivo. Biochem. Biophys. Res. Commun. 233: 231.
53. Qian J X, Lee S M, Suen Y, Knoppel E, van De Ven C, Cairo M S. 1997. Decreased interleukin-15 from activated cord versus adult peripheral blood mononuclear cells and the effect of interleukin-15 in upregulating antitumor immune activity anti cytokine production in cord blood. Blood 90: 3106.
54. Cao S, Troutt A B, Rustum Y M. 1998. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res. 58: 1695.
55. Tsung K, Meko J B, Tsung Y L, Peplinski G R, Norton J A. 1998. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J. Immunol. 160: 1369.